Health
Opaganib shows promise in preventing ARDS-induced thrombosis – Drug Target Review
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Posted: 16 December 2020 | Hannah Balfour (Drug Target Review) | No comments yet
Opaganib reduced blood clot length and weight in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
Opaganib (Yeliva®), a novel, orally administered sphingosine kinase 2 (SK2) selective inhibitor, (administered at 250mg/kg,) reduced thrombosis in a preclinical model of Acute Respiratory Distress Syndrome (ARDS).
According to the researchers, their findings suggest opaganib may be of benefit to patients…
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
General24 hours agoLiberals dump NSW candidate who said women should not serve in ADF combat
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts